WASHINGTON, Oct 2 (Reuters) - Trubion Pharmaceuticals Inc., which is creating a pipeline of product candidates to treat autoimmune disease and cancer, said on Monday it is planning to issue 4 million shares for $13 to $15 per share in an initial public offering.
